Fresenius Medical Care

Advancing in kidney care

11/07/19 -"The US government’s announcement has brought some clarity about how care might be provided in the future. As administration is involved, it still seems to be a long time before implementation. ..."

PDF page sample
Pages
67
Language
English
Published on
11/07/19
Download
You may also be interested by these reports :
24/06/25
FMC has expanded its savings goals beyond the FME25 programme, targeting approximately €750 million in savings by 2025, with an additional €300m by ...
17/06/25
Expectations may have been overly optimistic, or FMC may not have provided the necessary information. Despite presenting numerous details, a ...
17/06/25
We have cut our FY2025 EPS estimates to factor in: 1. A softer than expected showing in China, as reflected in the H1 2025 performance 2. Ongoing ...
12/06/25
Total gross assets increased from €7.99bn to €8.38bn. This growth is primarily driven by upwardly-revised multiples and stronger 5 year average ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO